Chemotherapy-related cardiotoxicity: New diagnostic and preventive strategies

Italian Heart Journal

Volumn 4, Issue 10, 2003, Pages 655-667

  Benvenuto, Giuseppe Marino ^a,d   Ometto, Renato ^a   Fontanelli, Alessandro ^a   Fortunato, Antonio ^b   Ruffini, Pier Adelchi ^c   Fosser, Vinicio ^d   Morandi, Paolo ^d  

^a Cardiology Unit   (Italy)

^b San Bartolo Hospital   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d SAN BORTOLO HOSPITAL   (Italy)

Author keywords

Cardiotoxicity; Diastolic function; Natriuretic peptides; Systolic function; Tissue Doppler imaging; Troponins

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN 1; TROPONIN;

BLOOD; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; FEMALE; FORWARD HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HOSPITALIZATION; HUMAN; MALE; METHODOLOGY; NEOPLASM; PREDICTION AND FORECASTING; PRIMARY PREVENTION; PROGNOSIS; QUALITY OF LIFE; REVIEW; SENSITIVITY AND SPECIFICITY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CARDIAC OUTPUT, LOW; ENDOTHELIN-1; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PRIMARY PREVENTION; PROGNOSIS; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TROPONIN; VENTRICULAR DYSFUNCTION, LEFT;

EID: 1542646978     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (139)

1. Antman KH. A critique of the eleven randomised trials of high-dose chemotherapy for breast cancer. Eur J Cancer 2001; 37: 173-9.
2. Lefrak EA, Pitha J, Rosheneim S, Gottlieb JA. A clinico-pathological analysis of adryamicin cardiotoxicity. Cancer 1973; 32: 302-14.
3. Praga C, Beretta G, Vigo PL, et al. Adryamicin cardiotoxicity. A survey of 1273 patients. Cancer Treat Rep 1979; 63: 827-34.
4. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000; 22: 263-302.
5. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758-63.
6. Ayash LJ, Wright JE, Tretyakov O, et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992; 10: 995-1000.
7. Braveman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation. A prospective evaluation of new dosing regimens. J Clin Oncol 1991; 9: 1215-23.
8. Singal PK, Iliskovic N. Doxorubin-induced cardiomyopathy. N Engl J Med 1998; 339: 900-5.
9. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 2002; 234-235: 119-24.
10. Minotti G, Saponiero A, Licata S, et al. Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res 2001; 7: 1511-5.
11. Perez EA. Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations. Cancer Invest 2001; 19: 155-64.
12. Feldman AM, Lorell BH, Reis SE. Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation 2000; 102: 272-4.
13. Ewer MS, Gibbs HR, Swafford J, Benjamin RS. Cardiotoxicity in patients receiving trastuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifacts? Semin Oncol 1999; 26 (Suppl 12): 96-101.
14. Schneider JW, Chang AY, Garratt A. Trastuzumab cardiotoxicity: speculations regarding pathophysiology and targets for further study. Semin Oncol 2002; 29 (Suppl 11): 22-8.
15. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998; 25 (Suppl 10): 72-85.
16. Mason JW, Bristow MR, Billingham ME, et al. Invasive and noninvasive methods of assessing adryamicin cardiotoxic effects in man: superiority of histopathological assessment using endomyocardial biopsy. Cancer Treat Rep 1978; 62: 873-9.
17. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective blinded long-term observational study of outcome in 120 patients. Ann Oncol 2002; 13: 699-709.
18. Moreb JS, Oblon DJ. Outcome of clinical congestive heart failure induced by anthracycline chemotherapy. Cancer 1992; 70: 2637-41.
19. Keefe DL. Anthracycline-induced cardiomyopathy. Semin Oncol 2001; 28 (Suppl 12): 2-7.
20. Thomas X, Le QH, Fiere D. Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyeolocytic leukemia. Ann Hematol 2002; 81: 504-7.
21. Kremer LC, Van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002; 13: 919-29.
22. Lipshultz SE, Lipsitz SR, Mone SR, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1738-43.
23. Meinardi MT, Van Veldhuisen DJ, Gietema JA, et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 2001; 19: 2746-53.
24. Ritchie JL, Bateman TM, Bonow RO, et al. Guidelines for clinical use of cardiac radionuclide imaging. Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures, in collaboration with the American Society of Nuclear Cardiology. J Am Coll Cardiol 1995; 25: 521-47.
25. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children Cancer Study Group. Pediatrics 1992; 89: 942-9.
26. Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol 2003; 10: 132-9.
27. Sabel MS, Levine EG, Hurd T, et al. Is MUGA scan necessary in patients with low-risk breast cancer before doxorubicin-based adjuvant therapy? Am J Clin Oncol 2001; 24: 425-8.
28. Von Hoff DD, Lajard MW, Basa P, et al. Risks factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-7.
29. Ryberg M, Nielsen D, Skovskaard T, et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998; 16: 3502-8.
30. 2) cyclophosphamide. Bone Marrow Transplant 2001; 28: 277-82.
31. Benvenuto GM, La Vecchia L, Morandi P, Ruffini PA, Mezzena G. Analisi della cardiotossicità da ciclofosfamide ad alte dosi mediante monitoraggio elettrocardiografico, ecocardiografico e della troponina I in pazienti con tumore della mammella. Ital Heart J Suppl 2000; 1: 1457-63.
32. Minow RA, Benjamin RS, Lee ET, Gottlieb JA. QRS voltage change with adryamicin administration. Cancer Treat Rep 1978; 62: 931-4.
33. Larsen RL, Jakacki RI, Vetter VL, et al. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 1992; 70: 73-7.
34. Schwartz CL, Hobbie WL, Truesdell S, et al. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol 1993; 11: 1906-10.
35. Ferrari S, Figus E, Cagnano R, Iantorno D, Bacci G. The role of corrected QT interval in the cardiologic follow-up of young patients treated with adryamicin. J Chemother 1996; 8: 232-6.
36. Fukumi D, Uchikoba Y, Maeda M, Ogawa S. Longitudinal evaluation of anthracycline cardiotoxicity by signal-averaged electrocardiography in children with cancer. Pediatr Int 2002; 44: 134-40.
37. Nakamae H, Tsumura M, Hayashi T, Tatsumi N. QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide. Lancet 2000; 355: 805-6.
38. Scwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiography. Am J Med 1987; 82: 1109-18.
39. Druck MN, Gulendin KY, Evans WK, et al. Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity. Cancer 1984; 53: 1667-74.
40. McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. Sensitivity and specificity of radionuclide ejection fraction in doxorubicin cardiotoxicity. Am Heart J 1983; 106: 1048-56.
41. Palmeri ST, Bonow RO, Myers CE, et al. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol 1986; 58: 607-13.
42. Hutter JJ, Sahn DJ, Woolfenden JM, Carnahan Y. Evaluation of the cardiac effects of doxorubicin by serial echocardiography. Am J Dis Child 1981; 135: 653-7.
43. Sung RY, Huang GY, Shing MK, et al. Echocardiographic evaluation of cardiac function in pediatric oncology patients treated with or without anthracyclines. Int J Cardiol 1997; 60: 239-48.
44. Alexander J, Dainiak N, Berger HJ, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiography. N Engl J Med 1979; 300: 278-83.
45. Weesner KM, Bledsoe M, Chauvenet A, Wofford M. Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer 1991; 68: 435-8.
46. Hauser M, Gibson BS, Wilson N. Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress-echocardiography. Eur J Pediatr 2001; 160: 607-10.
47. Klewer SE, Goldberg SJ, Donnerstein RL, Berg RA, Hutter JJ. Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. J Am Coll Cardiol 1992; 19: 394-401.
48. De Wolf D, Suys B, Maurus R, et al. Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors. Pediatr Res 1996; 39: 504-12.
49. Allen J, Thomson JD, Lewiss IJ, Gibbs JL. Mitral regurgitation after anthracycline treatment for childhood malignancy. Heart 2001; 85: 369-70.
50. Giannuzzi P, Temporelli PL, Bosimini E, et al. Independent and incremental prognostic value of Doppler-derived mitral deceleration time of early filling in both symptomatic and asymptomatic patients with left ventricular dysfunction. J Am Coll Cardiol 1996; 28: 383-90.
51. Lee BH, Goodenday LS, Muswick GJ, et al. Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol 1987; 9: 184-8.
52. Stoddard MF, Seeger J, Liddell NE, et al. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 1992; 20: 62-9.
53. Marchandise B, Schoeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989; 118: 92-8.
54. Hashimoto I, Ichida F, Miura M, et al. Automatic border detection identifies subclinical anthracycline cardiotoxicity in children with malignancies. Circulation 1999; 99: 2367-70.
55. Lele SS, Durrant ST, Atherton JJ, et al. Demonstration of late cardiotoxicity following bone marrow transplantation by assessment of exercise diastolic filling characteristics. Bone Marrow Transplant 1996; 17: 1113-8.
56. Cottin Y, L'Huillier I, Casanovas O, et al. Dobutamine stress echocardiography identifies anthracycline cardiotoxicity. Eur J Echocardiogr 2000; 1: 180-3.
57. Ishii M, Tsutsumi T, Himeno W, et al. Sequential evaluation of left ventricular myocardial performance in children after anthracycline therapy. Am J Cardiol 2000; 86: 1279-81.
58. Eidem BW, Sapp BG, Suarez CR, Cetta F. Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children. Am J Cardiol 2001; 87: 1120-2.
59. Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone. J Am Coll Cardiol 1997; 30: 8-18.
60. Cohen GI, Pietrolungo JF, Thomas JD, Klein AL. A practical guide to assessment of ventricular diastolic function using Doppler echocardiography. J Am Coll Cardiol 1996; 27: 1753-60.
61. Brun P, Tribouilloy C, Duval AM, et al. Left ventricular flow propagation during early filling is related to wall relaxation: a color M-mode analysis. J Am Coll Cardiol 1992; 20: 420-32.
62. Nagueh S, Middleton K, Kopelen H, Zoghbi W, Quinones M. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997; 30: 1527-33.
63. Yalcin F, Kaftan A, Muderrisoglu H, et al. Is Doppler tissue velocity during early left ventricular filling period preload independent? Heart 2002; 87: 336-9.
64. Garcia MJ, Smedira NG, Greenberg NL, Main M, Firstemberg MS, Thomas JD. Color M-mode Doppler flow propagation velocity is a preload insensitive index of left ventricular relaxation: animal and human validation. J Am Coll Cardiol 2000; 35: 201-8.
65. Firstemberg MS, Greenberg NL, Prior DL, McCarty PM, Garcia MJ, Thomas JD. Relationship between early diastolic intraventricular pressure gradient, an index of elastic recoil, and improvement in systolic and diastolic function. Circulation 2001; 104: 1330-5.
66. Stugaard M, Smiseth OA, Risoe C, Ihlen H. Intraventricular early diastolic filling during acute myocardial ischemia assessment by multigated color M-mode Doppler echocardiography. Circulation 1993; 88: 2705-13.
67. Moller JE, Sondergaard E, Seward JB, Appleton CP, Egstrup K. Ratio of left ventricular peak E wave velocity to flow propagation velocity assessed by color M-mode Doppler echocardiography in first myocardial infarction: prognostic and clinical implications. J Am Coll Cardiol 2000; 35: 363-70.
68. Palka P, Lange A, Fleming AD, et al. Differences in myocardial velocity gradient measured throughout the cardiac cycle in patients with hypertrophic cardiomyopathy, athletes and patients with left ventricular hypertrophy due to hypertension. J Am Coll Cardiol 1997; 30: 760-8.
69. Benvenuto GM, Morandi P, Merlini L, et al. Analysis of conventional and newer Doppler indexes of systolic and diastolic function for early detection of chemotherapy-induced cardiomyopathy. (abstr) Ital Heart J 2003, in press.
70. Kapusta L, Thijssen JM, Groot-Loonen J, Antonius T, Mulder J, Daniels O. Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines. Ultrasound Med Biol 2000; 26: 1099-108.
71. Kapusta L, Thijssen JM, Groot-Loonen J, van Druten JA, Daniels O. Discriminative ability of conventional echocardiography and tissue Doppler imaging techniques for the detection of subclinical cardiotoxic effects of treatment with anthracyclines. Ultrasound Mol Biol 2001; 27: 1605-14.
72. Takenaka K, Kuwada Y, Sonoda M, et al. Anthracycline-induced cardiomyopathies evaluated by tissue Doppler tracking system and strain rate imaging. J Cardiol 2001; 37 (Suppl 1): 129-32.
73. Tassan-Mangina S, Brasselet C, Nazeyrollas P, et al. Value of pulsed Doppler tissue imaging for early detection of myocardial dysfunction with anthracyclines. Arch Mal Coeur Vaiss 2002; 95: 263-8.
74. Edner M, Jarnet C, Muller-Brunotte R, et al. Influence of age and cardiovascular factors on regional pulsed wave Doppler myocardial imaging indices. Eur J Echocardiogr 2000; 1: 87-95.
75. Sutherland GR, Hatle L. Pulsed Doppler myocardial imaging. A new approach to regional longitudinal function. Eur J Echocardiogr 2000; 1: 81-3.
76. Naito J, Masujama T, Mano T, et al. Ultrasonic myocardial tissue characterization in patients with dilated cardiomyopathy: value in noninvasive assessment of myocardial fibrosis. Am Heart J 1996; 131: 115-21.
77. Bigras JL, McCrindle BW, Shibuya K, Smallhorn JF. Abnormal ultrasonic tissue characterization of the myocardium in children receiving doxorubicin for cancer therapy. Echocardiography 1998; 15: 121-6.
78. Ponikowski P, Anker SD, Chua TP, et al. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1997; 79: 1645-50.
79. Fauchier L, Babuty D, Cosnay P, Autret ML, Fauchier JP. Heart rate variability in idiopathic dilated cardiomyopathy: characteristics and prognostic value. J Am Coll Cardiol 1997; 30: 1009-14.
80. Brouwer J, van Veldhuisen DJ, Man in't Veld AJ, et al. Prognostic value of heart rate variability during long-term follow-up in patients with mild to moderate heart failure. The Dutch Ibopamine Multicenter Trial Study Group. J Am Coll Cardiol 1996; 28: 1183-9.
81. Postma A, Bink-Boelkens MT, Beaufort-Krol GC, et al. Late cardiotoxicity after treatment for malignant bone tumor. Med Pediatr Oncol 1996; 26: 230-7.
82. Tjeerdsma G, Meinardi MT, van der Graaf WT, et al. Early detection of anthracycline-induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart 1999; 81: 419-23.
83. Meinardi MT, van der Graaf WT, van Veldhuisen DJ, Gietema JA, de Vries EG, Sleijfer DT. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 1999; 25: 237-47.
84. Davidson NC, Struthers AD. Brain natriuretic peptide. J Hypertens 1994; 12: 329-36.
85. Talwar S, Squire IB, Downie PF, Davies JE, Ng LL. Plasma N-terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart 2000; 844: 21-4.
86. Karl J, Borgya A, Gallusser A, et al. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest 1999; 59: 177-81.
87. Kikuta K, Yasue H, Yoshimura M, et al. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. Am Heart J 1996; 132: 101-7.
88. Talwar S, Squire IB, Downie PF, et al. Profile of plasma N-terminal proBNP following acute myocardial infarction: correlation with left ventricular systolic function. Eur Heart J 2000; 21: 1514-21.
89. Morita E, Yasue H, Yoshimura M, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993; 88: 82-91.
90. Kohno M, Horio T, Yokokawa K, et al. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor. Am J Med 1995; 98: 257-65.
91. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
92. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001; 37: 379-85.
93. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001; 141: 367-74.
94. Andersson B, Hall C. N-terminal proatrial natriuretic peptide and prognosis in patients with heart failure and preserved systolic function. J Card Fail 2000; 6: 208-13.
95. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001; 37: 386-91.
96. Tsutamoto T, Wada A, Maeda K, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction: comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999; 20: 1799-807.
97. Yu CM, Sanderson JE, Shum IO, et al. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J 1996; 17: 1694-702.
98. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma N-terminal natriuretic peptide concentrations. Lancet 2000; 355: 1126-30.
99. Mair J, Hammerer-Lercher A, Pushendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001; 39: 571-88.
100. Hetmanski DJ, Sparrow NJ, Curtis S, Cowley AJ. Failure of plasma brain natriuretic peptide to identify left ventricular systolic dysfunction in the community. Heart 2000; 84: 440-1.
101. Struthers AD. Plasma concentrations of brain natriuretic peptide: will this new test reduce the need for cardiac investigations? Br Heart J 1993; 70: 397-8.
102. Wright SP, Doughty RN. Natriuretic peptides in the evaluation of suspected heart failure: studies in primary care are needed. Eur Heart J 2000; 21: 594-5.
103. Struthers AD. N-terminal proBNP: the most cost-effective way to identify post myocardial infarction left ventricular dysfunction? Eur Heart J 2000; 21: 1490-2.
104. Suzuki T, Hayashi D, Yamazaki T, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998; 136: 362-3.
105. Nousiainen T, Vanninen E, Jantunen E, et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 2002; 251: 228-34.
106. Nousiainen T, Jantunen E, Vanninen E, Remes J, Vuolteenaho O, Hartikainen J. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol 1999; 62: 135-41.
107. Snowden JA, Hill GR, Hunt P, et al. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant 2000; 26: 309-13.
108. Hokumura H, Iuchi K, Yoshida T, et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 2000; 104: 158-63.
109. Benvenuto GM, Morandi P, Merlini L, Fortunato A, Ometto R, Fontanelli A. Anthracycline cardiotoxicity monitoring by conventional echo-Doppler and tissue-Doppler imaging: its relationship with pro-brain natriuretic peptide. (abstr) Barcelona, 2003, in press.
110. Stubbs P. The cardiac troponins: uses in routine clinical practice. Experience from GUSTO and other clinical trials. Eur Heart J 1998; 19 (Suppl N): N59-N63.
111. Falahati A, Sharkey SW, Christensen D, et al. Implementation of serum cardiac troponin I as marker for detection of acute myocardial infarction. Am Heart J 1999; 137: 332-7.
112. Lauer B, Niederau C, Kuhl U, et al. Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol 1997; 30: 1354-9.
113. La Vecchia L, Mezzena G, Ometto R, et al. Detectable serum troponin I in patients with heart failure of nonmyocardial ischemic origin. Am J Cardiol 1997; 80: 88-90.
114. Sato Y, Yamada T, Taniguchi R, et al. Serum concentration of cardiac troponin T in patients with cardiomyopathy: a possible mechanism of acute heart failure. Heart 1998; 80: 209-10.
115. Ottani F, Galvani M, Ferrini D, et al. Direct comparison of early elevations of cardiac troponin T and I in patients with clinical unstable angina. Am Heart J 1999; 137: 284-91.
116. Stromme JH, Johansen O, Brekke M, Seljeflot I, Arnesen H. Markers of myocardial injury in blood following PTCA: a comparison of CKMB, cardiospecific troponin T and troponin I. Scand J Clin Lab Invest 1998; 58: 693-9.
117. Antman EM, Tanasjievic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335: 1342-9.
118. Herman EH, Zhang J, Lipshultz SE, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999; 17: 2237-43.
119. Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997; 96: 2641-8.
120. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36: 517-22.
121. Cardinale D, Sandri MT, Martinoni A, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002; 13: 710-5.
122. Fink FM, Genser N, Fink C, et al. Cardiac troponin T and creatine kinaseMB mass concentrations in children receiving anthracycline therapy. Med Pediatr Oncol 1995; 25: 185-9.
123. Raderer M, Kornek G, Weinlander G, Kastner J. Serum troponin T levels in adults undergoing anthracycline therapy. (letter) J Natl Cancer Inst 1997; 89: 171.
124. Auner HW, Tinchon C, Brezinschek RI, et al. Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamide. Eur J Haematol 2002; 69: 1-6.
125. Kremer LC, Bastiaansen BA, Offringa M, et al. Troponin T in the first 24 hours after the administration of chemotherapy and the detection of myocardial damage in children. Eur J Cancer 2002; 38: 686-9.
126. Sparano JA, Brown DL, Wolff AC. Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers. Drug Saf 2002; 25: 301-11.
127. Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994; 89: 1580-6.
128. Porta C, Moroni M, Ferrari S, Nastasi G. Endothelin-1 and 5-fluorouracil-induced cardiotoxicity. Neoplasma 1998; 45: 81-2.
129. de Groote P, Millaire A, Racadot A, Decoulx E, Ducloux G. Plasma levels of endothelin-1 at rest and after exercise in patients with moderate congestive heart failure. Int J Cardiol 1995; 51: 267-72.
130. Suzuki T, Miyauchi T. A novel pharmacological action of ET-1 to prevent the cytotoxicity of doxorubicin in cardiomyocytes. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1399-R1406.
131. Yamashita J, Ogawa M, Shirakusa T. Plasma endothelin-1 as a marker for doxorubicin cardiotoxicity. Int J Cancer 1995; 62: 542-7.
132. Tallarico D, Rizzo V, Di Maio F, et al. Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy. Angiology 2003; 54: 219-27.
133. Andrieu-Abadie N, Jaffrezou JP, Hatem S, Laurent G, Levade T, Mercaider JJ. L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes; role of inhibition of ceramide generation. FASEB J 1999; 13: 1501-10.
134. Yaris N, Ceviz N, Coskum T, Akytuz C, Buyukpamucku M. Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity. J Exp Clin Cancer Res 2002; 21: 165-70.
135. Mordente A, Meucci E, Martorana GE, Giardina B, Minotti G. Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 2001; 52: 83-8.
136. Iarussi D, Auricchio U, Agretto A, et al. Protective effect of coenzyme Q10 on anthracycline cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med 1994; 15: 207-12.
137. Horenstein MS, Vander Heide RS, L'Ecuyer TJ. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab 2000; 71: 436-44.
138. 2 cumulative dose of Doxil. (abstr) Proc Am Soc Clin Oncol 2000; 19: 206A.
139. Fazio S, Palmieri EA, Ferravante B, Bone F, Biondi B, Sacca L. Doxorubicin-induced cardiomyopathy treated with carvedilol. Clin Cardiol 1998; 21: 777-9.